CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to SNY

Insulin glargine/lixisenatide fixed ratio combination

Phase 3
Sanofi (SNY)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

6

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Type 2 Diabetes Mellitus

Clinical Trial

NCT02787551

Last updated: 12/8/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMAPending

Ondibta

Treatment of diabetes mellitus

View on EMA
EMA3/23/2018

Semglee

Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.

View on EMA
EMA1/3/2017

Lusduna

Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.

View on EMA
EMA9/9/2014

Abasaglar (previously Abasria)

Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.

View on EMA
EMA1/31/2013

Lyxumia

Lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.

View on EMA
EMA6/26/2000

Toujeo (previously Optisulin)

Treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years.

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.